An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism von Ptacin, Jerod L., Caffaro, Carolina E., Ma, Lina, San Jose Gall, Kristine M., Aerni, Hans R., Acuff, Nicole V., Herman, Rob W., Pavlova, Yelena, Pena, Michael J., Chen, David B., Koriazova, Lilia K., Shawver, Laura K., Joseph, Ingrid B., Milla, Marcos E.

Volltext

A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism von Ptacin, Jerod L., Ma, Lina, Caffaro, Carolina E., Acuff, Nicole V., Germar, Kristine, Severy, Peter, Qu, Yanyan, Vela, Jose-Luis, Cai, Xinming, San Jose, Kristine M., Aerni, Hans R., Chen, David B., Esche, Ean, Ismaili, Taylor K., Herman, Rob, Pavlova, Yelena, Pena, Michael J., Nguyen, Jasmine, Koriazova, Lilia K., Shawver, Laura K., Joseph, Ingrid B., Mooney, Jill, Peakman, Mark, Milla, Marcos E.

Volltext

Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases von Sun, Li, Tran, Ngoc, Liang, Congxin, Tang, Flora, Rice, Audie, Schreck, Randall, Waltz, Kara, Shawver, Laura K, McMahon, Gerald, Tang, Cho

Volltext

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant von Millauer, Birgit, Shawver, Laura K, Plate, Karl H, Risaui, Werner, Ullrich, Axel

Volltext

The Angiogenesis Inhibitor SU5416 Has Long-lasting Effects on Vascular Endothelial Growth Factor Receptor Phosphorylation and Function von MENDEL, Dirk B, SCHRECK, Randall E, WEST, David C, GUANGMIN LI, STRAWN, Laurie M, TANCIONGCO, Sheila S, VASILE, Stefan, SHAWVER, Laura K, CHERRINGTON, Julie M

Volltext

Blockade of the Epidermal Growth Factor Receptor Tyrosine Kinase Suppresses Tumorigenesis in MMTV/Neu + MMTV/TGF-α Bigenic Mice von Anne E. G. Lenferink, Simpson, Jean F., Shawver, Laura K., Coffey, Robert J., Forbes, James T., Arteaga, Carlos L.

Volltext

Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas von Zajchowski, Deborah A, Karlan, Beth Y, Shawver, Laura K

Volltext

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth... von FONG, T. A. T, SHAWVER, L. K, ULLRICH, A, HIRTH, K. P, MCMAHON, G, LI SUN, CHO TANG, APP, H, POWELL, T. J, KIM, Y. H, SCHRECK, R, XUEYAN WANG, RISAU, W

Volltext

A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates von Ma, Lina, Acuff, Nicole V., Joseph, Ingrid B., Ptacin, Jerod L., Caffaro, Carolina E., San Jose, Kristine M., Aerni, Hans R., Carrio, Roberto, Byers, Anthony M., Herman, Rob W., Pavlova, Yelena, Pena, Michael J., Chen, David B., Buetz, Christen, Ismaili, Taylor K., Pham, Helene V., Cucchetti, Margot, Sassoon, Ingrid, Koriazova, Lilia K., Leveque, Joseph A., Shawver, Laura K., Mooney, Jill M., Milla, Marcos E.

Volltext

Smart drugs: Tyrosine kinase inhibitors in cancer therapy von Shawver, Laura K, Slamon, Dennis, Ullrich, Axel

Volltext

Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo von MILLAUER, B, LONGHI, M. P, PLATE, K. H, SHAWVER, L. K, RISAU, W, ULLRICH, A, STRAWN, L. M

Volltext

Flk-1 as a target for tumor growth inhibition von STRAWN, L. M, MCMAHON, G, CHEN, I, KERI, G, ORFI, L, RISAU, W, FLAMME, I, ULLRICH, A, HIRTH, K. P, SHAWVER, L. K, APP, H, SCHRECK, R, KUCHLER, W. R, LONGHI, M. P, HUI, T. H, TANG, C, LEVITZKI, A, GAZIT, A

Volltext

Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site von Arteaga, Carlos L., Ramsey, Timothy T., Shawver, Laura K., Guyer, Cheryl A.

Volltext

Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials von Strawn, Laurie M, Shawver, Laura K

Volltext

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416 von Sukbuntherng, Juthamas, Cropp, Gillian, Hannah, Alison, Wagner, Gregory S., Shawver, Laura K., Antonian, Lida

Volltext

THOR-707: Using synthetic biology to reprogram the therapeutic activity of interleukin-2 (IL-2) von Milla, Marcos E, Ptacin, Jerod, Caffaro, Carolina E., Aerni, Hans R., Ma, Lina, Koriazova, Lilia, Joseph, Ingrid B., Shawver, Laura K.

Volltext

Recombinant Immunotoxins Directed against the c-erb-2/HER2/neu Oncogene Product: In Vitro Cytotoxicity, Pharmacokinetics, and in Vivo Efficacy Studies in Xenograft Models von ROSENBLUM, M. G, SHAWVER, L. K, MARKS, J. W, BRINK, J, CHEUNG, L, LANGTON-WEBSTER, B

Volltext

Correlation of tumor-profiling results with drug selection in ovarian cancer patients von Shawver, Laura K., Zajchowski, Deborah A.

Volltext

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors von LAIRD, A. D, VAJKOCZY, P, FONG, T. A. T, STRAWN, L. M, LI SUN, CHO TANG, HAWTIN, R, TANG, F, SHENOY, N, HIRTH, K. P, MCMAHON, G, CHERRINGTON, J. M, SHAWVER, L. K, THURNHER, A, CONGXIN LIANG, MOHAMMADI, M, SCHLESSINGER, J, ULLRICH, A, HUBBARD, S. R, BLAKE, R. A

Volltext

Abstract 58: Differences in genomic alterations revealed by sequencing of 182 genes in recurrent ovarian cancer specimens compared to TCGA analysis: rearrangements in PTCH1 and FLT... von Zajchowski, Deborah A., Lipson, Doron, Palmer, Gary, Shawver, Laura K.

Volltext